Ownership history in EntryPoint Capital, LLC Β· 6 quarters on record
This page tracks every 13F SEC filing in which EntryPoint Capital, LLC reported a position in FULGENT GENETICS INC (FLGT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π EntryPoint Capital, LLC underperformed the S&P 500 by β6.5% annually on this FLGT position. Timing score: 75% (3/4 decisions correct). Average cost basis: $20.47. Maximum drawdown during holding period: β15.0%.
β Significantly underperformed the S&P 500 by 6.5% ann.
4 quarters analyzed
π― Smart timing β consistently buying dips and trimming near peaks.
3 of 4 add/trim decisions correct
Best entry: $18.47 (2024 Q4) Β· Worst: $21.70 (2024 Q1)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
3 adds Β· 3 trims. Bought during 1 of 1 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.08% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size